Understanding Lung Cancer

Lung cancer starts when malignant cells grow in the lungs. It’s the most common cancer diagnosis worldwide, and in India, around 136,000 people receive this diagnosis every year. The disease doesn’t discriminate — while smokers make up the majority of cases, roughly 15-20% of people diagnosed have never smoked. Air pollution, radon exposure, asbestos contact, and family history all play roles. Early detection makes a real difference in treatment outcomes and quality of life.

Your lungs are responsible for breathing oxygen into your body and removing carbon dioxide. When cancer develops, it can interfere with this important process and spread to other organs if left untreated. Modern medicine now offers targeted treatments designed for specific mutations, immunotherapy that trains your immune system to fight cancer cells, and surgical techniques that preserve lung function. Understanding your diagnosis, treatment options, and what to expect helps you make informed decisions with your doctor.

At HealOnco, we treat lung cancer with precision and compassion. Our team coordinates imaging, biopsy results, molecular testing, and treatment planning so you get the right therapy for your exact cancer type. We’ve seen patients return to work, travel, and enjoy their families during and after treatment. Your journey with lung cancer doesn’t have to mean months away from home.

Types of Lung Cancer

Early Warning Signs

1. A cough that lasts longer than 2-3 weeks — whether you’re a smoker or not. Any new or worsening cough warrants investigation.
2. Coughing up blood or rust-colored sputum — even small amounts should be reported to your doctor immediately.
3. Chest pain or discomfort when breathing deeply — pain that gets worse when you cough, breathe in, or laugh.
4. Shortness of breath or wheezing — either persistent or appearing suddenly. This can happen if a tumor narrows an airway.
5. Hoarseness in your voice — lasting more than a few weeks, without an obvious cause like a cold.
6. Persistent fatigue — unusual tiredness that doesn’t improve with rest, affecting your work or daily life.
7. Unexplained weight loss — losing 5 kg or more without intentionally dieting or changing your exercise routine.
8. Recurrent respiratory infections — pneumonia or bronchitis that keeps returning to the same area of the lungs.
9. Shoulder or upper back pain — particularly on one side, especially if it worsens when you breathe or cough.
10. Swelling in the face or neck — caused by a tumor blocking blood vessels returning from the head to the heart.

If you notice any of these, see a doctor. In most cases the cause turns out to be benign, but the only way to be sure is an evaluation.

Risk Factors for Lung Cancer

How Lung Cancer is Diagnosed

Lung Cancer Staging (AJCC 8th Edition)

Treatment Modalities

Surgery

Surgery aims to remove the tumor and surrounding lung tissue with margin-negative resection (no cancer at the edge). The operation you receive depends on tumor size, location, and your lung function. VATS (video-assisted thoracoscopic surgery) lobectomy is minimally invasive: the surgeon uses a camera and instruments through 2-3 small incisions, removes the affected lobe, and drains adjacent lymph nodes. Recovery is 2-4 weeks, and most patients go home in 3-5 days. Open lobectomy via thoracotomy is used for larger or more complex tumors: an 8-10 cm incision allows direct visualization and removal. Recovery takes 4-6 weeks, and hospitalization is 5-7 days.

Wedge resection removes a small portion of lung containing the tumor; it’s used only for Stage IA tumors <2 cm in patients with severe COPD or poor lung function because recurrence risk is higher than with lobectomy. Segmentectomy removes a defined segment of lung (smaller than a lobe but larger than wedge); it's a middle option for small tumors in patients wanting to preserve lung. Pneumonectomy removes an entire lung; it's reserved for large central tumors or those crossing the main bronchus. This is major surgery with longer recovery (6-8 weeks) and is used sparingly because patients lose 50% lung capacity.

Robotic-assisted surgery (da Vinci system) is increasingly available in major Indian cancer centers. The surgeon sits at a console and controls robotic arms with 3D visualization and wristed instruments. Benefits include smaller incisions, reduced blood loss, and precise lymph node dissection. Operative time is longer than VATS, but recovery is similar (2-4 weeks). Cost is higher (₹2-3 lakhs extra) but justified for complex tumors. Your surgeon will recommend the approach best suited to your tumor’s location and your anatomy.

• VATS (video-assisted thoracoscopic) lobectomy — minimally invasive, 2-3 small incisions, suitable for most early-stage tumors <5 cm
• Open lobectomy via thoracotomy — standard for tumors >5 cm or complex central tumors
• Segmentectomy — for Stage IA tumors <2 cm in patients wanting to preserve lung function
• Wedge resection — only for very small peripheral tumors ≤2 cm and high-risk surgical patients; higher recurrence risk
• Pneumonectomy — for large central tumors crossing main bronchus or main pulmonary artery; removes entire lung
• Robotic-assisted thoracoscopic surgery (da Vinci) — emerging option in major centers, similar recovery to VATS but with enhanced 3D visualization and precision

Chemotherapy

Chemotherapy uses drugs that kill rapidly dividing cancer cells. For lung cancer, platinum-based regimens are backbone of first-line therapy. Cisplatin is the preferred agent but causes more side effects (nausea, kidney toxicity, hearing loss) than carboplatin; carboplatin is chosen if kidney function is borderline. These are paired with a second agent based on histology: for non-squamous adenocarcinoma, pemetrexed (Alimta) is preferred; for squamous-cell or mixed histology, gemcitabine is common. A typical regimen is cisplatin 75 mg/m² day 1 plus pemetrexed 500 mg/m² day 1, given every 3 weeks for 4-6 cycles. Each cycle is 21 days.

Before each chemotherapy cycle, blood work checks your white blood cells (WBC), hemoglobin, and platelet counts. If counts are too low, the cycle is delayed 1-2 weeks to recover. Side effects peak days 7-14 after treatment: nausea (managed with ondansetron or aprepitant), low blood counts requiring G-CSF shots, and fatigue. Mouth sores and diarrhea occur in 10-30% of patients and are managed with topical treatments and antidiarrheals. Peripheral neuropathy (numbness in fingers and toes) from taxanes (paclitaxel, docetaxel) can linger months after treatment.

Adjuvant chemotherapy (after surgery) for Stage IB-III NSCLC reduces 5-year recurrence risk by 5-15% and improves survival. It’s offered to patients who tolerate surgery well and recover in 4-6 weeks. Neoadjuvant chemotherapy (before surgery) for Stage IIIA shrinks the tumor, making surgery easier and improving resectability. For advanced (Stage IV) NSCLC without targetable mutations, first-line chemotherapy plus immunotherapy (pembrolizumab) is standard, extending median survival to 12-14 months. In India, generic cisplatin costs ₹2,000-4,000 per cycle; pemetrexed generics cost ₹15,000-25,000 per dose. Total cost per patient: ₹2-4 lakhs for 4-6 cycles at private hospitals.

• Cisplatin (75 mg/m² IV day 1) + Pemetrexed (500 mg/m² IV day 1) — every 3 weeks × 4-6 cycles; first-line for non-squamous NSCLC
• Cisplatin (75 mg/m² IV day 1) + Gemcitabine (1000 mg/m² IV days 1, 8) — every 3 weeks × 4-6 cycles; for squamous-cell NSCLC
• Carboplatin (AUC 5 IV day 1) + Paclitaxel (200 mg/m² IV day 1) — every 3 weeks × 4-6 cycles; alternative to cisplatin-based, less toxic
• Carboplatin (AUC 5) + Pemetrexed (500 mg/m²) — every 3 weeks × 4-6 cycles; for patients with cisplatin contraindication
• Dose-dense: Carboplatin (AUC 6) + Paclitaxel (100 mg/m²) weekly × 12 weeks — research regimen showing improved outcomes in fit patients
• Etoposide (120 mg/m² IV days 1-3) + Cisplatin (60 mg/m² IV day 1) — for SCLC, every 3 weeks × 4-6 cycles

Targeted Therapy: EGFR Inhibitors

EGFR mutations (most commonly exon 19 deletions and exon 21 L858R point mutation) occur in 40-50% of adenocarcinomas and are more common in never-smokers and Asian populations. Patients with EGFR-mutant tumors respond dramatically to EGFR tyrosine kinase inhibitors (TKIs). First-generation inhibitors like gefitinib (Iressa, 250 mg daily) and erlotinib (Tarceva, 150 mg daily) achieve response rates of 70-80% and median progression-free survival (PFS) of 10-13 months. Second-generation inhibitors like afatinib (Giotrif, 40 mg daily) are more potent but have higher toxicity.

Osimertinib (Tagrisso, 80 mg daily) is a third-generation EGFR TKI that crosses the blood-brain barrier and covers both sensitizing mutations and the T790M resistance mutation that emerges during treatment. First-line osimertinib has median PFS of 18-20 months, superior to first-generation inhibitors. This is now preferred first-line therapy for EGFR-mutant Stage IV NSCLC. Side effects are mild: acneiform rash in 50%, managed with skin care and topical corticosteroids, is actually associated with better response. Diarrhea occurs in 30-40% and improves with loperamide.

For EGFR-mutant Stage I-III NSCLC after complete resection, adjuvant osimertinib (80 mg daily for 3 years) after chemotherapy and/or radiation significantly improves 5-year survival compared to observation. This is now standard of care. Cost in India: gefitinib/erlotinib generics ₹8,000-15,000/month; osimertinib brand (Tagrisso) ₹55,000-65,000/month or generic ₹20,000-35,000/month. Most patients stay on EGFR inhibitors for 1-3 years until resistance develops, at which point osimertinib is added if not already on it, or other therapies are explored.

• Gefitinib (Iressa) — 250 mg orally daily; first-line for EGFR-sensitizing mutations, oral tablet
• Erlotinib (Tarceva) — 150 mg orally daily; first-line for EGFR mutations, oral tablet
• Osimertinib (Tagrisso) — 80 mg orally daily; preferred first-line for EGFR-mutant NSCLC, covers T790M resistance
• Afatinib (Giotrif) — 40 mg orally daily; second-generation EGFR TKI with higher toxicity, for patients failing first-generation TKI
• Dacomitinib (Vizimpro) — 45 mg orally daily; irreversible pan-HER inhibitor for EGFR-mutant NSCLC

Targeted Therapy: ALK Inhibitors

ALK (anaplastic lymphoma kinase) rearrangements occur in 3-5% of NSCLC, predominantly in never-smokers and younger patients with adenocarcinoma. These tumors are highly responsive to ALK inhibitors. Crizotinib (Xalkori, 250 mg twice daily) was the first-generation ALK inhibitor and achieves response rates of 60-65% with median PFS of 7-9 months. However, central nervous system (CNS) penetration is poor, and brain metastases develop in many patients during treatment.

Second-generation ALK inhibitors have better CNS penetration and overcome crizotinib resistance. Alectinib (Alunbrig, 600 mg twice daily) achieves median PFS of 25-27 months as first-line therapy and superior brain metastasis control. Lorlatinib (Lorbrena, 100 mg daily) is even more potent, with median PFS of 18-24 months and excellent CNS activity. These are now preferred over crizotinib as first-line agents for ALK-rearranged NSCLC. Side effects are manageable: alectinib may cause constipation and elevated creatinine (reversible); lorlatinib can cause elevated cholesterol and glucose.

For Stage I-III ALK-rearranged NSCLC after surgery and/or chemotherapy, adjuvant alectinib significantly improves disease-free survival compared to observation. Patients typically remain on ALK inhibitors for 2-3 years until resistance emerges (new mutations like G1269A), at which point lorlatinib or switching to chemotherapy may be considered. In India, crizotinib generics cost ₹8,000-12,000/month; alectinib brand ₹40,000-50,000/month or generic ₹15,000-25,000/month; lorlatinib is less available but estimated ₹50,000+/month.

• Crizotinib (Xalkori) — 250 mg orally twice daily; first-generation ALK inhibitor, now largely replaced by second-generation agents
• Alectinib (Alunbrig) — 600 mg orally twice daily; second-generation ALK inhibitor, superior CNS penetration and PFS vs. crizotinib
• Lorlatinib (Lorbrena) — 100 mg orally daily; third-generation ALK inhibitor with best CNS penetration and activity against crizotinib/alectinib-resistant mutations
• Ceritinib (Zykadia) — 450 mg orally daily with food; second-generation ALK inhibitor, alternative to alectinib if intolerance
• Brigatinib (Alunbrig alternative dosing) — 180 mg orally daily or 90 mg daily × 7 days then 180 mg; second-generation ALK inhibitor with rapid onset

Targeted Therapy: ROS1 Inhibitors

ROS1 rearrangements occur in 1-2% of NSCLC and confer sensitivity to crizotinib, the same drug used for ALK inhibitors. Crizotinib (250 mg twice daily) achieves response rates of 70% and median PFS of 19-21 months in ROS1-rearranged NSCLC, superior to its ALK activity. CNS metastases still develop in some patients because crizotinib has limited blood-brain barrier penetration.

Next-generation ROS1 inhibitors like entrectinib (Rozlytrek, 600 mg daily) and repotrectinib (emerging) have better CNS activity and overcome crizotinib-resistant mutations. Entrectinib can be used if CNS disease is present or develops. For most patients, crizotinib remains first-line due to cost and effectiveness, with switching to entrectinib upon progression. Side effects are similar to ALK inhibitor use: GI upset, hyperuricemia (gout risk), elevated liver enzymes.

ROS1-rearranged NSCLC is rare, and prospective data are limited compared to EGFR and ALK. However, response rates are high, and median overall survival approaches 3-5 years with sequential ROS1 inhibitor therapy. In India, crizotinib generics cost ₹8,000-12,000/month. Entrectinib brand is limited availability and expensive (₹70,000+/month). Most patients start crizotinib and continue until progression.

• Crizotinib (Xalkori) — 250 mg orally twice daily; first-line for ROS1-rearranged NSCLC, achieves 70% response rate
• Entrectinib (Rozlytrek) — 600 mg orally daily; next-generation ROS1 inhibitor with superior CNS penetration, for crizotinib resistance or CNS disease
• Repotrectinib (investigational) — preclinical/early clinical data, expected to be more potent ROS1 inhibitor

Targeted Therapy: KRAS Inhibitors

KRAS mutations occur in 30-40% of lung adenocarcinomas and historically had no targeted therapy, forcing patients onto chemotherapy or immunotherapy. The FDA approval of KRAS G12C inhibitors in 2021 transformed treatment for this large population. Sotorasib (Lumykras, 960 mg daily) and adagrasib (Krazati, 600 mg twice daily) specifically target the KRAS G12C mutation by binding the nucleotide exchange site and trapping KRAS in its inactive state.

Sotorasib achieves response rates of 30-40% and median PFS of 10-12 months when given as monotherapy for Stage IV NSCLC. Response rates improve to 50-60% when combined with pembrolizumab or other immunotherapy agents. Adagrasib shows similar activity. For patients with KRAS G12C mutations and no other targetable mutations, adding an EGFR inhibitor (gefitinib) or immunotherapy to KRAS inhibitor is being explored in clinical trials.

KRAS G12C inhibitors are relatively new, and long-term data are limited. These drugs work best in tumors with KRAS G12C alone; tumors with concurrent TP53 mutations or STK11 loss may have worse outcomes. Cost in India is still high: sotorasib brand ₹80,000-100,000/month; adagrasib similar. Generic versions may become available in 2-3 years, making treatment more accessible. Toxicity is low: diarrhea (20%), rash (10%), elevated liver enzymes (10%), manageable with supportive care.

• Sotorasib (Lumykras) — 960 mg orally daily; KRAS G12C inhibitor, 40% response rate as monotherapy in advanced NSCLC
• Adagrasib (Krazati) — 600 mg orally twice daily; KRAS G12C inhibitor, similar efficacy to sotorasib
• Sotorasib + Pembrolizumab (200 mg IV every 3 weeks) — combination showing 50-60% response rate, synergistic benefit

Immunotherapy (Checkpoint Inhibitors)

Immunotherapy drugs release the brakes on your immune system’s T cells, allowing them to recognize and kill cancer cells. PD-1 inhibitors (pembrolizumab, nivolumab) and PD-L1 inhibitors (atezolizumab, durvalumab) work by blocking the interaction between tumor cells (which express PD-L1) and immune cells (which express PD-1 receptors). This reactivates exhausted T cells. For advanced NSCLC without targetable mutations and high PD-L1 expression (≥50%), pembrolizumab monotherapy (200 mg IV every 3 weeks) achieves median PFS of 10-13 months and median OS of 15-20 months.

For tumors with lower PD-L1 expression or to maximize response, chemotherapy is added: cisplatin-pemetrexed plus pembrolizumab (given concurrently weeks 1-4, then pembrolizumab alone) improves median OS to 15-18 months in first-line metastatic NSCLC. This combination is standard of care. Toxicity is generally lower than chemotherapy alone, but immune-related adverse events (irAEs) occur in 20-30%: fatigue (most common), rash, diarrhea, thyroid dysfunction, and rarely, severe colitis or pneumonitis requiring steroids and hospitalization.

For Stage III locally advanced NSCLC after chemoradiation, consolidation durvalumab (10 mg/kg IV every 2 weeks × 4 weeks then every 4 weeks × up to 12 months) significantly improves PFS and OS compared to observation alone. This is now standard after concurrent chemoradiation. For SCLC, atezolizumab or durvalumab added to chemotherapy in first-line extends median OS by 2-4 months. In India, nivolumab brand (Opdivo) ₹35,000-50,000/dose; pembrolizumab (Keytruda) ₹40,000-60,000/dose; generics pending. Most patients continue immunotherapy 1-2 years until progression or intolerable toxicity.

• Pembrolizumab (Keytruda) — 200 mg IV every 3 weeks; PD-1 inhibitor, monotherapy for PD-L1 ≥50% Stage IV NSCLC
• Nivolumab (Opdivo) — 360 mg IV every 4 weeks or 240 mg every 2 weeks; PD-1 inhibitor, alternative to pembrolizumab
• Atezolizumab (Tecentriq) — 1200 mg IV every 3 weeks; PD-L1 inhibitor, used in Stage IV NSCLC and SCLC
• Durvalumab (Imfinzi) — 10 mg/kg IV every 2 weeks; PD-L1 inhibitor, consolidation after chemoradiation for Stage III NSCLC
• Ipilimumab (Yervoy) — 1 mg/kg IV every 3 weeks × 4 doses; CTLA-4 inhibitor, combined with nivolumab for select Stage IV NSCLC with high tumor burden
• Pembrolizumab + Cisplatin-Pemetrexed — chemotherapy given weeks 1-4, then pembrolizumab monotherapy; first-line metastatic NSCLC

Radiation Therapy

Radiation therapy uses high-energy X-rays or protons to kill cancer cells. For early-stage (Stage I-II) NSCLC patients who cannot or refuse surgery, stereotactic body radiation therapy (SBRT, also called SABR) is highly effective: 3-5 high-dose fractions (18-24 Gy per fraction) delivered over 1-2 weeks achieves local control rates of 85-95% and 5-year survival of 40-50%, competitive with surgery. SBRT is outpatient, no anesthesia, minimal side effects.

For locally advanced (Stage III) NSCLC, concurrent chemoradiation is standard: chemotherapy (cisplatin-etoposide) given weekly or every 3 weeks alongside 3D conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT), total dose 60-66 Gy in 30-33 daily fractions (2 Gy per fraction). Concurrent therapy improves median OS compared to sequential therapy. IMRT uses computer-optimized beams to spare normal lung and heart from high doses, reducing toxicity. Proton therapy is emerging for similar indications with potentially lower late toxicity but high cost (₹15-20 lakhs).

Prophylactic cranial irradiation (PCI) is given to SCLC patients achieving complete response: 25 Gy in 10 daily fractions over 2 weeks reduces brain metastases from 60% to 15-20% and improves overall survival by 5-10%. Brain metastases from NSCLC are managed with stereotactic radiosurgery (SRS, single high-dose fraction to each lesion) if 1-3 lesions, or whole-brain radiation (30 Gy in 10 fractions) if >3 lesions. Acute side effects include fatigue, skin redness, and cough (if lungs treated); late effects (months-years later) include radiation pneumonitis (1-5%), esophagitis (if mediastinum treated), and cardiac toxicity (rare with modern techniques).

• SBRT/SABR (Stereotactic Body/Ablative Radiation Therapy) — 3-5 fractions of 18-24 Gy, total 54-60 Gy over 1-2 weeks; first-line for medically inoperable Stage I-II NSCLC
• 3D-CRT (3D Conformal Radiation Therapy) — 60-66 Gy in 30-33 daily 2 Gy fractions over 6-7 weeks; concurrent with chemotherapy for Stage III NSCLC
• IMRT (Intensity-Modulated Radiation Therapy) — 60-66 Gy in 30-33 fractions with computer-optimized beam intensity; reduces normal tissue toxicity vs. 3D-CRT
• Proton Beam Therapy — 60-66 Gy equivalent in 30-33 fractions; emerging modality with reduced late toxicity to lung/heart, expensive
• Prophylactic Cranial Irradiation (PCI) — 25 Gy in 10 fractions for SCLC complete responders; reduces brain metastases from 60% to 15%
• Stereotactic Radiosurgery (SRS) — single 15-24 Gy fraction per lesion; for brain metastases from lung cancer, 1-3 lesions

Symptom Management & Palliative Care

Palliative care focuses on comfort and quality of life, not cure. It’s integrated early in advanced lung cancer and continues alongside active treatment. Breathlessness (dyspnea) is treated with supplemental oxygen if oxygen saturation drops below 90%, bronchodilators (albuterol nebulizer), and low-dose opioids (morphine 5-10 mg orally 4-6 hourly, or sustained-release 15-30 mg twice daily) which reduce breathlessness sensation by dampening respiratory centers. Anxiety exacerbates breathlessness; anxiolytics like lorazepam (0.5-1 mg) help.

Cough is managed based on cause: productive cough may improve with mucolytics (bromhexine) or chest physiotherapy; dry cough responds to suppressants (dextromethorphan, codeine, or low-dose morphine). Pain from chest wall or bone metastases is treated with NSAIDs (ibuprofen 400-600 mg TDS), acetaminophen, weak opioids (tramadol, codeine), or strong opioids (morphine, fentanyl patch) titrated to effect. Fatigue from cancer or treatment is multifactorial: optimize anemia, ensure adequate nutrition, encourage gentle exercise, and consider psychostimulants (methylphenidate) for severe cases.

Nausea and loss of appetite are common in advanced cancer. Antiemetics include ondansetron (8 mg IV or orally 8-hourly), dexamethasone (4-8 mg daily for appetite stimulation), and metoclopramide (10 mg 30 minutes before meals). Appetite stimulants like megestrol acetate (800 mg daily) may help. Psychosocial support—counseling, support groups, spiritual care—addresses emotional suffering. Hospice care at home provides comfort care in the final weeks of life with goals aligned to patient values. Palliative care improves quality of life and mood, and when done well, may even extend survival by reducing treatment-related complications.

• Morphine (immediate-release) — 5-10 mg orally/IV every 4-6 hours; for pain, breathlessness, cough; dose titrated to effect
• Morphine (sustained-release) — 15-30 mg orally twice daily; for continuous pain management in advanced cancer
• Fentanyl patch — 12-100 mcg/72 hours; for chronic pain in opioid-tolerant patients, changed every 3 days
• Ondansetron (Zofran) — 8 mg IV or orally 8-hourly; 5-HT3 antagonist for chemotherapy or cancer-related nausea
• Dexamethasone — 4-8 mg orally daily; for nausea, anorexia, and appetite stimulation in advanced cancer
• Metoclopramide — 10 mg orally 30 minutes before meals; for nausea and gastroparesis
• Albuterol nebulizer — 2.5 mg in 3 mL saline via nebulizer 4-6 hourly; for breathlessness
• Lorazepam — 0.5-1 mg orally or IV 6-12 hourly; for anxiety-related breathlessness
• Megestrol acetate — 800 mg orally daily; appetite stimulant for cachexia
• Methylphenidate — 5-20 mg orally twice daily; psychostimulant for fatigue

Why Adjuvant & Neoadjuvant Therapy Matters

After you have surgery to remove a lung tumor, microscopic cancer cells may still hide in your body. These cells are invisible on scans but can grow into full-blown tumors years later. Adjuvant chemotherapy (given after surgery) targets these hidden cells and reduces the recurrence risk by 5-15%. For Stage II and select Stage IB tumors, this improves 5-year survival significantly. You tolerate adjuvant chemotherapy better than during active disease because you’re recovering from surgery and your overall health is often better.

Neoadjuvant therapy works the opposite direction. If your tumor is large or fixed to nearby structures (Stage IIIA), chemotherapy or chemoradiation is given before surgery to shrink it. This makes surgery technically easier, removes the blood supply to the tumor, and improves the chances that the surgeon can remove all visible disease. Patients who respond well to neoadjuvant therapy have better long-term survival. Think of it as preparing the battlefield before going in.

The decision to pursue adjuvant or neoadjuvant therapy is personalized. Your oncologist considers tumor size, grade, lymph node involvement, molecular mutations, and your fitness for treatment. At HealOnco, we discuss these options thoroughly, explain realistic benefits and side effects, and help you decide what aligns with your goals. Some patients decline adjuvant therapy due to side effects; this is a valid choice if the benefit is modest. Others choose aggressive treatment because they want to minimize recurrence risk. Both approaches are reasonable with informed consent.

A Day at HealOnco: Your Lung Cancer Treatment Journey

Treatment Cost Breakdown in India

Our Lung Cancer Specialists

Our Centres

Modern Day-Care vs. Traditional Hospitalization

Understanding Side Effects

Every cancer treatment can cause side effects. Your oncologist will explain what to expect based on your specific treatment plan and how the team will manage any issues that arise. Common concerns include fatigue, nausea, and changes in blood counts — all of which are closely monitored at HealOnco.

Read the full side effects guide for Lung Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Lung Cancer Treatment in Top Cities

Lung Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. Globocan 2022: Global Cancer Observatory. India Lung Cancer Incidence & Mortality. World Health Organization International Agency for Research on Cancer. www.iarc.who.int
2. Indian Council of Medical Research (ICMR). National Cancer Registry Programme: Incidence of Cancer in India 2019-2021. Government of India Ministry of Health. www.icmr.gov.in
3. SEER Database: Surveillance, Epidemiology, and End Results Program. 5-Year Survival Rates for Lung Cancer by Stage. National Cancer Institute. seer.cancer.gov
4. Mathur P, Srivastava S, Sullivan R, et al. Lung Cancer in India: A Systematic Review and Meta-analysis. JCLI. 2020;11(7):e1354. PubMed PMID 32857053. www.ncbi.nlm.nih.gov
5. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer, Version 2.2025. National Comprehensive Cancer Network. www.nccn.org
6. Reck M, Rodriguez-Abreu D, Robinson AG, et al. KEYNOTE-024: Pembrolizumab versus chemotherapy for first-line treatment of advanced PD-L1 high NSCLC. N Engl J Med. 2016;375(19):1823-1833. pubmed.ncbi.nlm.nih.gov
7. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv192-iv237. www.esmo.org
8. Soria JC, Ohe Y, Vansteenkiste J, et al. FLAURA: Afatinib versus gefitinib as first-line treatment of ALK-positive NSCLC. J Clin Oncol. 2018;36(20):2042-2050. pubmed.ncbi.nlm.nih.gov
9. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957. IPASS trial. pubmed.ncbi.nlm.nih.gov
10. WHO: Air Pollution and Your Health. Fact Sheet. 2022. Particulate matter and lung cancer risk. www.who.int
11. Indian Network for Organ Preservation (INOP). National guidelines for lung cancer screening in high-risk populations. Presented at Indian Association of Medical Oncologists 2024. www.iamo.org.in
12. Government of India Ministry of Health & Family Welfare. Ayushman Bharat Scheme Coverage for Cancer Treatment. 2024. ayushman.gov.in